Spots Global Cancer Trial Database for A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
Official Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Study ID: NCT02137343
Conditions
Study Description
Brief Summary: This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced mesenchymal epithelial transition factor (MET)-positive gastric or gastroesophageal junction adenocarcinoma (GEJ).
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Nagoya-shi, Aichi, Japan
Research Site, Chiba-shi, Chiba, Japan
Research Site, Kashiwa-shi, Chiba, Japan
Research Site, Matsuyama-shi, Ehime, Japan
Research Site, Fukuoka-shi, Fukuoka, Japan
Research Site, Sapporo-shi, Hokkaido, Japan
Research Site, Akashi-shi, Hyogo, Japan
Research Site, Kawasaki-shi, Kanagawa, Japan
Research Site, Osaka-shi, Osaka, Japan
Research Site, Osaka-shi, Osaka, Japan
Research Site, Osakasayama-shi, Osaka, Japan
Research Site, Suita-shi, Osaka, Japan
Research Site, Takatsuki-shi, Osaka, Japan
Research Site, Kitaadachi-gun, Saitama, Japan
Research Site, Suntou-gun, Shizuoka, Japan
Research Site, Utsunomiya-shi, Tochigi, Japan
Research Site, Bunkyo-ku, Tokyo, Japan
Research Site, Goyang-si, Gyeonggi-do, , Korea, Republic of
Research Site, Hwasun, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
